MaxCyte (MXCT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual Meeting scheduled for June 17, 2026, to elect three Class II directors and ratify the selection of CohnReznick LLP as independent auditor for fiscal year 2026.
Record date for voting is April 21, 2026, with 107,121,672 shares outstanding and entitled to vote.
Proxy materials are available online, and shareholders are encouraged to vote via internet, phone, or mail.
Voting matters and shareholder proposals
Shareholders will vote on the election of Patrick Balthrop, Cynthia Collins, and Stanley Erck as Class II directors for terms expiring in 2029.
Ratification of CohnReznick LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Shareholder proposals for the 2027 meeting must be submitted by December 30, 2026, with director nominations due between February 17 and March 19, 2027.
Board of directors and corporate governance
Board consists of nine members divided into three classes, with a majority deemed independent under Nasdaq standards.
Board leadership is separated, with an independent chairman and CEO roles held by different individuals.
Board diversity matrix shows two female and seven male directors, with representation from Asian, Middle Eastern, and White backgrounds.
Board and committees met regularly, with all members attending at least 75% of meetings.
Committees include Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.
Code of Conduct and Ethics, insider trading policies, and corporate governance guidelines are in place.
Latest events from MaxCyte
- Q1 2025 revenue fell 8% to $10.4M, but core business grew and guidance is reaffirmed.MXCT
Q1 20259 Jul 2026 - Q2 2024 revenue up 15% to $10.4M, SPL revenue surged 279%, and cash guidance raised to $180M.MXCT
Q2 20249 Jul 2026 - Q3 revenue rose 2% to $8.2M, core revenue up 23%, and six new SPLs set a record.MXCT
Q3 20249 Jul 2026 - Restructuring, SecureDx integration, and new launches set the stage for global growth in 2026.MXCT
Stephens Annual Investment Conference8 Jul 2026 - Electroporation and SPL growth drive strong momentum in cell and gene therapy markets.MXCT
Stifel 2024 Healthcare Conference8 Jul 2026 - 2025 guidance targets 8–15% core revenue growth and $5M SPL revenue, leveraging SeQure Dx.MXCT
Q4 20248 Jul 2026 - Q1 2026 revenue fell 7%, net loss narrowed, and a $10M share repurchase was authorized.MXCT
Q1 202613 May 2026 - Vote on three director nominees and auditor ratification at the June 17, 2026 annual meeting.MXCT
Proxy filing29 Apr 2026 - 2025 revenue fell 15%, but cost cuts and new launches set up a back-half 2026 recovery.MXCT
Q4 202527 Mar 2026